TG Therapeutics Inc. (NASDAQ:TGTX) shares dropped 6.3% on Tuesday . The company traded as low as $5.92 and last traded at $5.97, with a volume of 258,785 shares changing hands. The stock had previously closed at $6.37.

TGTX has been the subject of a number of recent research reports. FBR & Co reiterated a “buy” rating on shares of TG Therapeutics in a research note on Wednesday, May 4th. HC Wainwright reiterated a “buy” rating and issued a $22.00 price objective on shares of TG Therapeutics in a research note on Thursday, March 10th. Brean Capital reiterated a “buy” rating on shares of TG Therapeutics in a research note on Monday, June 13th. Roth Capital reiterated a “buy” rating and issued a $33.00 price objective on shares of TG Therapeutics in a research note on Thursday, June 9th. Finally, SunTrust Banks Inc. initiated coverage on shares of TG Therapeutics in a research note on Friday, May 27th. They issued a “buy” rating and a $18.00 price objective for the company. One analyst has rated the stock with a sell rating, five have assigned a buy rating and two have issued a strong buy rating to the company’s stock. TG Therapeutics has a consensus rating of “Buy” and an average target price of $22.33.

The stock’s market capitalization is $326.08 million. The company’s 50-day moving average price is $7.10 and its 200-day moving average price is $8.58.

TG Therapeutics (NASDAQ:TGTX) last issued its earnings results on Tuesday, May 10th. The biopharmaceutical company reported ($0.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.36) by $0.08. Equities research analysts anticipate that TG Therapeutics Inc. will post ($1.15) earnings per share for the current fiscal year.

In related news, CFO Sean A. Power sold 10,000 shares of the stock in a transaction that occurred on Monday, April 18th. The shares were sold at an average price of $10.12, for a total transaction of $101,200.00. Following the transaction, the chief financial officer now owns 466,682 shares in the company, valued at $4,722,821.84. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

A hedge fund recently raised its stake in TG Therapeutics stock. Columbus Circle Investors increased its position in shares of TG Therapeutics Inc. (NASDAQ:TGTX) by 6.7% during the fourth quarter, Holdings Channel reports. The firm owned 705,389 shares of the biopharmaceutical company’s stock after buying an additional 44,190 shares during the period. Columbus Circle Investors owned about 1.34% of TG Therapeutics worth $8,415,000 at the end of the most recent quarter.

TG Therapeutics, Inc (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for b-cell malignancies and autoimmune diseases. As of December 31, 2014, TG had two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the CD20 antigen found on mature B-lymphocytes.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.